68Ga-DOTATOC与18F-FDG双显像PET用于神经内分泌肿瘤PRRT联合替莫唑胺治疗的规划与随访
本文报道一名68岁原发灶不明的转移性神经内分泌肿瘤患者,FDG摄取提示部分去分化的转移灶。联合治疗后所有肿瘤病灶包括FDG阳性病灶均显示非常好的反应。
要点
- 68Ga-DOTATOC与18F-FDG双显像PET可识别神经内分泌肿瘤中的去分化转移灶。
- 既往多线治疗失败的转移性NET患者,PRRT联合替莫唑胺仍可能获得很好反应。
- FDG阳性去分化病灶在联合治疗后同样显示良好反应。
核心结论
- 对于原发灶不明的转移性神经内分泌肿瘤患者,68Ga-DOTATOC与18F-FDG双显像PET有助于发现部分去分化的转移灶并为PRRT联合替莫唑胺治疗提供规划与随访依据。
研究设计与样本
- 本文为单例病例报告,报道一名68岁原发灶不明的转移性神经内分泌肿瘤患者。
主要发现
- 68Ga-DOTATOC与18F-FDG PET双显像显示该患者存在部分去分化的转移灶(FDG摄取阳性)。
- 患者既往接受生物治疗、依维莫司、5周期肽受体放射性核素治疗、放疗及双膦酸盐和RANKL抑制剂骨保护治疗,每项治疗均暂时延缓疾病进展。
临床怎么用
- 对转移性神经内分泌肿瘤患者,可考虑68Ga-DOTATOC与18F-FDG双显像PET评估病灶分化状态并指导PRRT规划。
- 对多线治疗后进展的转移性NET患者,PRRT联合替莫唑胺可作为可选治疗策略并在治疗后进行影像随访。
局限性
- 本文为单例病例报告,证据级别有限,结论不能直接推广至所有转移性神经内分泌肿瘤患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 68-year-old man with a metastatic neuroendocrine tumor with unknown primary was found to have partially dedifferentiated metastases according to F-FDG uptake. He received 3 cycles of radiopeptide therapy using [Lu]Lutetium-DOTATATE combined with temozolomide. Before this treatment, the patient had already undergone a series of therapies, including biotherapy, everolimus, 5 cycles of radiopeptide therapies, radiotherapy, and bone-protecting therapy with bisphosphonate and receptor activator of NF-κB ligand, each of which temporarily stalled the progress of the disease. After combined treatment with radiopeptide therapy and temozolomide, the patient showed a very good response in all tumor lesions, including the FDG-positive ones.
引用
- Wei X, Hain S, Hartmann L, et al. Dual Imaging With 68Ga-DOTATOC and 18F-FDG PET for Planning and Follow-up of PRRT in Combination With Temozolomide Treatment in a Patient With a Metastatic Neuroendocrine Tumor. Clin Nucl Med. 2019. PMID: 30829861. doi:10.1097/RLU.0000000000002519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。